Key points from article :
Anirvan Ghosh, Unity Biotechnology: clinical trial to determine the maximum safe single dose of its proprietary senolytic compound, UBX1325, that targets Bcl-xL.
Lloyd Klickstein, ResTORbio: phase 3 trial of BEZ235 did not meet its primary endpoint - potentially due to the different survey methods.
Ronald Kohanski, NIA: believes best time for anti-aging interventions is ~30 years old in humans.
Adam Freund, Calico: focused on IGF signaling through the inhibition of PAPP-A - may restore collagen deposition with age.
Gordon Lithgow, Buck Institute: using C. elegans for large-scale drug screening. Compressed morbidity seen with TFT, AKG & vit D.
Steven Braithwhite, Alkahest: Sifting plasma proteome. GRF6019 stalled cognitive decline in some patients with mild to moderate AD.
Aubrey de Grey, SENS Research Foundation: over a hundred startups in aging research, but field still in its infancy.
Reenie McCarthy, Stealth BioTherapeutics: Elamipretide normalizes mitochondrial morphology by reducing the production of toxic ROS.
Alex Zhavoronkov, Insilico: looking at link between cellular senescence and fibrosis.
Brian Culley, Lineage Cell Therapeutics: uses fully differentiated cell transplantation.
Marc Ramis-Castelltort, Rejuveron: funds and supports start-ups including Endogena, RejuverVas & RejuverSen.
Colin Watts, JuvLife: developing supplements - first may be a ketone ester.
Scott Shandler, Longevity Biotech: preclinical programs in neuroinflammation, diabetes & oncology.
Marco Quarta, Rubedo: creating prodrugs which are more stable and less toxic.
Andrei Gudkov, Genome Protection: anti-retrobiome vaccine demonstrated decreased frailty in mice.
Lewis Gruber, Siwa Therapeutics: claims monoclonal antibody 318H can be used against virtually all cancers.
Thomas Hughes, Navitor Pharmaceuticals: developed rapamycin analogs less toxic to mTORC2.
Samuel Agus, Biophytis: BIO101 normalizes angiotensin production, reduces hypertension, inflammation & fibrosis.
